NOC
43
11
BF.B
33
2
MCD
52
2
DVN
21
3
PSA
58
2
SE
61
-4
DD
63
3
CINF
53
2
INTC
33
-2
MPC
44
-3
HBI
59
4
NDAQ
62
2
EBAY
47
4
PBI
69
4
TXT
55
3
KLAC
47
4
DTE
56
2
XRX
44
3
CRM
67
2
SO
53
-4
NOC
43
11
BF.B
33
2
MCD
52
2
DVN
21
3
PSA
58
2
SE
61
-4
DD
63
3
CINF
53
2
INTC
33
-2
MPC
44
-3
HBI
59
4
NDAQ
62
2
EBAY
47
4
PBI
69
4
TXT
55
3
KLAC
47
4
DTE
56
2
XRX
44
3
CRM
67
2
SO
53
-4
Financhill
Back

Sarepta Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
33

SRPT
Sarepta Therapeutics

Last Price:
114.28
Seasonality Move:
16.38%

7 Day Trial

ALL ACCESS PASS

$ 7

Trade on Tuesday. Profit on Friday. Rinse & Repeat

Get the full details now.

Sarepta Therapeutics Price Quote

$114.28
+0.05 (+3.42%)
(Updated: November 23, 2024 at 5:55 AM ET)

Sarepta Therapeutics Key Stats

Sell
33
Sarepta Therapeutics (SRPT) is a Sell
Day range:
$110.50 - $114.83
52-week range:
$78.67 - $173.25
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
7.01
P/B ratio:
8.94%
Volume:
883.1K
Avg. volume:
978.6K
1-year change:
36.36%
Market cap:
$10.9B
Revenue:
$1.2B
EPS:
$1.54

How Much Does Sarepta Therapeutics Make?

Is Sarepta Therapeutics Growing As A Company?

  • What Is Sarepta Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.41%
  • What Is Sarepta Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Sarepta Therapeutics Stock Price Performance

What Is Sarepta Therapeutics 52-Week High & Low?

Sarepta Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Sarepta Therapeutics?

Is Sarepta Therapeutics Cash Flow Positive?

  • What Is SRPT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$352.5M
  • What Is Sarepta Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $77.8M
  • What Is Sarepta Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$72.9M

Sarepta Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    SRPT return on invested capital is 5.51%
  • What Is Sarepta Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 3.67%
  • What Is SRPT Return On Equity?
    ROE is a measure of profitability and is 12.48%

Sarepta Therapeutics Earnings Date & Stock Price

Sarepta Therapeutics Competitors

  • Who Are Sarepta Therapeutics's Competitors?
    Below is a list of companies who compete with Sarepta Therapeutics or are related in some way:
    • Catalyst Pharmaceuticals Inc (CPRX)
    • Eli Lilly and Co (LLY)
    • Regeneron Pharmaceuticals Inc (REGN)
    • Viking Therapeutics Inc (VKTX)
    • Vertex Pharmaceuticals Inc (VRTX)

Sarepta Therapeutics Dividend Yield

Sarepta Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 66.97%
Revenue: 40.79% 15.33%

Analyst Recommendations

Buy Recommendations: 12
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 189.62
Upside from Last Price: 66%

Major Shareholders

  • How many SRPT shares are owned by institutional investors?
    147.6M SRPT shares are owned by institutional investors
  • How many SRPT shares are owned by insiders?
    15.5M SRPT shares are owned by insiders